Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ImClone Erbitux Hearing Will Include Five FDAers Under Subpoena

Executive Summary

The House Energy & Commerce/Oversight Subcommittee has subpoenaed five FDA witnesses to appear at a June 13 hearing on issues surrounding the refuse-to-file letter for ImClone's Erbitux

You may also be interested in...



Unresolved Review Issues: Clinical Trials Are Easier Fix Than Safety, Efficacy

Problems with clinical trial design and/or execution identified pre-submission are the issues most likely to be resolved in advance of first FDA action, Booz Allen Hamilton's first-cycle review report finds

Erbitux Oncologic Potential Endorsed By FDA, Bristol During House Hearing

ImClone's oncologic agent Erbitux is "an active anticancer agent," Bristol-Myers Squibb and FDA Oncologic Drug Products Division Director Richard Pazdur, MD, agreed during a June 13 Energy & Commerce/Oversight Subcommittee hearing

Erbitux Oncologic Potential Endorsed By FDA, Bristol During House Hearing

ImClone's oncologic agent Erbitux is "an active anticancer agent," Bristol-Myers Squibb and FDA Oncologic Drug Products Division Director Richard Pazdur, MD, agreed during a June 13 Energy & Commerce/Oversight Subcommittee hearing

Related Content

UsernamePublicRestriction

Register

PS039973

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel